1. Cellular immunotherapy plus chemotherapy ameliorates survival in gastric cancer patients: a meta-analysis

   • Guoming Hu
   • Kefang Zhong
   • Liming Huang

   Review Article 30 July 2020 Pages: 1747 - 1756

   

2. Contrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective study

   • Ali Gökyer
   • Ahmet Küçükarda
   • İrfan Çiçin

   Original Article 26 June 2020 Pages: 1757 - 1762

   

3. Long-term cognitive outcome in adult survivors of an early childhood posterior fossa brain tumour

   • Adam P. Wagner
   • Cliodhna Carroll
   • Howard Ring

   Original Article Open access 08 July 2020 Pages: 1763 - 1773

   

4. The impact of clinicopathological factors on clinical outcomes in patients with salivary gland adenoid cystic carcinoma: a multi-institutional analysis in Japan

   • Daisuke Kawakita
   • Takayuki Murase
   • Hiroshi Inagaki

   Original Article 01 July 2020 Pages: 1774 - 1785

   

5. Why is renal impairment associated with poorer cancer specific survival in breast cancer patients?: a comparison with patients with other comorbidities

   • Andy Evans
   • Russell Petty
   • Jane Macaskill

   Original Article Open access 02 July 2020 Pages: 1786 - 1792

   

6. Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303)

   • Daisuke Kobayashi
   • Yoshinari Mochizuki
   • Yasuhiro Kodera

   Original Article 21 June 2020 Pages: 1793 - 1799

   

7. Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study

   • Shintaro Nakano
   • Satoshi Yuki
   • Yoshito Komatsu

   Original Article Open access 14 July 2020 Pages: 1800 - 1806

   

8. Comparison of 2- and 4-week S-1 administration as adjuvant chemotherapy for advanced gastric cancer

   • Koichi Ogawa
   • Michitaka Honda
   • Tatsuya Oda

   Original Article 12 June 2020 Pages: 1807 - 1813

   

9. Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial

   • Minoru Kobayashi
   • Ryuichiro Sato
   • Takashi Tsuchiya

   Original Article Open access 27 June 2020 Pages: 1814 - 1821

   

10. Clinicopathological characteristics and prognosis analysis of ovarian metastases in colorectal cancer: a single-center experience

    • Rui Zhou
    • Ya Liu
    • Tao Zhang

    Original Article 26 June 2020 Pages: 1822 - 1829

11. Incidence and risk factors of parastomal hernia after ileal conduit diversion in Japanese population

    • Kazutaka Maruo
    • Toshiaki Tanaka
    • Naoya Masumori

    Original Article 12 June 2020 Pages: 1830 - 1834

    

12. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)

    • Naohiro Okano
    • Chigusa Morizane
    • Junji Furuse

    Original Article 13 June 2020 Pages: 1835 - 1843

    

13. Focal therapy with high-intensity focused ultrasound for the localized prostate cancer for Asian based on the localization with MRI-TRUS fusion image-guided transperineal biopsy and 12-cores transperineal systematic biopsy: prospective analysis of oncological and functional outcomes

    • Sunao Shoji
    • Shinichiro Hiraiwa
    • Akira Miyajima

    Original Article 17 June 2020 Pages: 1844 - 1853

    

14. Evaluation of the concordance in HPV type between self- and physician-collected samples using a brush-based device and a PCR-based HPV DNA test in Japanese referred patients with abnormal cytology or HPV infection

    • Toshimichi Onuma
    • Tetsuji Kurokawa
    • Yoshio Yoshida

    Original Article Open access 24 June 2020 Pages: 1854 - 1860

15. Intracellular accumulation of PD-1 molecules in circulating T lymphocytes in advanced malignant melanoma: an implication for immune evasion mechanism

    • Ryo Takahashi
    • Yohei Sato
    • Manabu Ohyama

    Original Article 12 July 2020 Pages: 1861 - 1869

    

16. Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation

    • Yasutomo Teshima
    • Minako Kizaki
    • Miki Harumiya

    Original Article Open access 22 July 2020 Pages: 1870 - 1878

    

17. Correction to: Recent advances of the regulation roles of MicroRNA in glioblastoma

    • Chengrui Yan
    • Xiangyi Kong
    • Yuanli Zhao

    Correction 24 August 2020 Pages: 1879 - 1879